Policy Brief: 2026 International Reference Pricing / Most Favored Nation Model
This policy brief addresses the Trump Administration’s revived Most Favored Nation pricing push, including a 2025 executive order, manufacturer agreements, and proposed GLOBE/GUARD payment models). IVI cautions that importing foreign price benchmarks risks reducing healthcare value to price alone, potentially harming access and innovation unless it is paired with patient-centered, transparent value assessment. VIEW POLICY […]
Policy Brief: 2026 Inflation Reduction Act
The Medicare Drug Price Negotiation Program, established under the Inflation Reduction Act, has gone through three selection cycles (2023–2026), and in this policy brief, IVI argues CMS should anchor negotiated prices in broader patient-centered value—not just lower costs—while embedding equity, transparency, and real-world evidence into impplementation. VIEW POLICY BRIEF